发明名称 Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof
摘要 This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.
申请公布号 US8759341(B2) 申请公布日期 2014.06.24
申请号 US201013201482 申请日期 2010.02.05
申请人 Bayer Intellectual Property GmbH 发明人 Michels Martin;Follmann Markus;Vakalopoulos Alexandros;Zimmermann Katja;Lobell Mario;Teusch Nicole;Yuan Shendong
分类号 C07D401/04;C07D471/04;C07D491/048;C07D491/147;C07D491/153;C07D495/04;C07D498/14 主分类号 C07D401/04
代理机构 代理人
主权项 1. A compound of formula (I) wherein A is —C(═O)— or —S(═O)2—, D is —CR6AR6B—, —O— or —NR7—, wherein R6A, R6B and R7 are independently hydrogen or (C1-C4)-alkyl optionally substituted with hydroxy or up to three fluoro atoms, E is —CR8AR8B— or *—CR8AR8B—CR8CR8D—**, wherein * denotes the link to the dihydropyridine ring,** denotes the link to the D group,andR8A, R8B, R8C and R8D are independently hydrogen, fluoro or (C1-C4)-alkyl optionally substituted with hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino or di-(C1-C4)-alkylamino or up to three fluoro atoms,orR8A and R8B are joined and, taken together with the carbon atom to which they are attached, form a cyclopropyl or cyclobutyl ring, R1 is selected from the group consisting of hydrogen, chloro, bromo, (C1-C6)-alkyl, (C3-C7)-cycloalkyl, phenyl, 4- to 7-membered heterocycloalkyl, 5- to 10-membered heteroaryl and benzo-1,4-dioxanyl, wherein (i) said (C3-C7)-cycloalkyl, phenyl, 4- to 7-membered heterocycloalkyl and 5- to 10-membered heteroaryl are optionally substituted with one or two substituents independently selected from the group consisting of fluoro, chloro, bromo, difluoromethyl, trifluoromethyl, (C1-C4)-alkyl, oxo, hydroxy, difluoromethoxy, trifluoromethoxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino, (C3-C6)-cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein the alkyl groups of said (C1-C4)-alkoxy, mono-(C1-C4)-alkylamino and di-(C1-C4)-alkylamino substituents in turn are optionally substituted with hydroxy or (C1-C4)-alkoxy,and(ii) said (C1-C6)-alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of fluoro, trifluoromethyl, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino, (C3-C7)-cycloalkyl, phenyl, 4- to 7-membered heterocycloalkyl and 5- to 10-membered heteroaryl, wherein said (C3-C7)-cycloalkyl, phenyl, 4- to 7-membered heterocycloalkyl and 5- to 10-membered heteroaryl substituents in turn are optionally substituted with one or two residues independently selected from the group consisting of fluoro, chloro, bromo, difluoromethyl, trifluoromethyl, (C1-C4)-alkyl, oxo, hydroxy, difluoromethoxy, trifluoromethoxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino and di-(C1-C4)-alkylamino, or R1 is a group of the formula —NR9AR9B or —OR10, wherein R9A and R9B are independently selected from the group consisting of hydrogen, (C1-C6)-alkyl, (C3-C7)-cycloalkyl and 4- to 7-membered heterocycloalkyl, wherein (i) said (C3-C7)-cycloalkyl and 4- to 7-membered heterocycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of fluoro, difluoromethyl, trifluoromethyl, (C1-C4)-alkyl, oxo, hydroxy, difluoromethoxy, trifluoromethoxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino and di-(C1-C4)-alkylamino,and(ii) said (C1-C6)-alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of fluoro, trifluoromethyl, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino, (C3-C7)-cycloalkyl, phenyl, 4- to 7-membered heterocycloalkyl and 5- to 10-membered heteroaryl, wherein said (C3-C7)-cycloalkyl, phenyl, 4- to 7-membered heterocycloalkyl and 5- to 10-membered heteroaryl substituents in turn are optionally substituted with one or two residues independently selected from the group consisting of fluoro, chloro, bromo, difluoromethyl, trifluoromethyl, (C1-C4)-alkyl, oxo, hydroxy, difluoromethoxy, trifluoromethoxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino and di-(C1-C4)-alkylamino,orR9A and R9B are joined and, taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocycloalkyl ring, which may contain a second ring heteroatom selected from N, O and S, and which is optionally substituted with one or two substituents independently selected from the group consisting of fluoro, (C1-C4)-alkyl, oxo, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino and (C3-C6)-cycloalkyl,R10 is selected from the group consisting of (C1-C6)-alkyl, (C3-C7)-cycloalkyl and 4- to 7-membered heterocycloalkyl, wherein (i) said (C3-C7)-cycloalkyl and 4- to 7-membered heterocycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of fluoro, difluoromethyl, trifluoromethyl, (C1-C4)-alkyl, oxo, hydroxy, difluoromethoxy, trifluoromethoxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino and di-(C1-C4)-alkylamino,and(ii) said (C1-C6)-alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of fluoro, trifluoromethyl, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino, (C3-C7)-cycloalkyl, phenyl, 4- to 7-membered heterocycloalkyl and 5- to 10-membered heteroaryl, wherein said (C3-C7)-cycloalkyl, phenyl, 4- to 7-membered heterocycloalkyl and 5- to 10-membered heteroaryl substituents in turn are optionally substituted with one or two residues independently selected from the group consisting of fluoro, chloro, bromo, difluoromethyl, trifluoromethyl, (C1-C4)-alkyl, oxo, hydroxy, difluoromethoxy, trifluoromethoxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino and di-(C1-C4)-alkylamino, R2 is hydrogen, fluoro, chloro or methyl, R3 is hydrogen, (C1-C4)-alkyl or cyclopropyl, R4 is cyano or aminocarbonyl, R5 is selected from the group consisting of (C1-C6)-alkyl, (C3-C7)-cycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein (i) said (C3-C7)-cycloalkyl, phenyl and 5- or 6-membered heteroaryl are optionally substituted with one or two substituents independently selected from the group consisting of fluoro, chloro, bromo, cyano, difluoromethyl, trifluoromethyl, (C1-C4)-alkyl, hydroxy, difluoromethoxy, trifluoromethoxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino and di-(C1-C4)-alkylamino,and(ii) said (C1-C6)-alkyl is optionally substituted with up to three fluoro atoms or with one or two substituents independently selected from the group consisting of trifluoromethyl, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino, (C3-C7)-cycloalkyl, phenyl, 4- to 7-membered heterocycloalkyl and 5- or 6-membered heteroaryl, wherein the alkyl groups of said (C1-C4)-alkoxy, mono-(C1-C4)-alkylamino and di-(C1-C4)-alkylamino substituents in turn are optionally substituted with up to three fluoro atoms or with one or two residues independently selected from the group consisting of trifluoromethyl, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino and 4- to 7-membered heterocycloalkyl,and whereinsaid (C3-C7)-cycloalkyl, phenyl, 4- to 7-membered heterocycloalkyl and 5- or 6-membered heteroaryl groups in turn are optionally substituted with one or two residues independently selected from the group consisting of fluoro, chloro, cyano, trifluoromethyl, (C1-C4)-alkyl, oxo, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino and di-(C1-C4)-alkylamino, or R5 is (C1-C4)-alkoxycarbonyl, aminocarbonyl, mono-(C1-C4)-alkylaminocarbonyl or di-(C1-C4)-alkylaminocarbonyl, or R3 and R5 are joined and, taken together with the nitrogen and the carbon atom to which they are attached, form a fused ring of the formula wherein G is —CH2—, —C(CH3)2—, —CH(CF3)—, —O— or —NR11-, wherein R11 is hydrogen or (C1-C4)-alkyl, and R12A and R12B are independently hydrogen or fluoro, or R4 and R5 are joined and, taken together with the carbon atoms to which they are attached, form a fused lactone or lactame ring of the formula wherein M is —O— or —NR13—, wherein R13 is hydrogen or (C1-C4)-alkyl, or a pharmaceutically acceptable salt thereof.
地址 Monheim DE